A

ATTO

ATTO

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
75%Bullish
Buy/Sell Ratio92% buys
BearishBullish
ATTO Live QuoteReal-time
$15.10
+$0.60(+4.14%)1M
Day Range$14.80 – $15.46
Open$15.40
Previous Close$15.58
Volume372.2K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$709.92M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-5.53
Price to Book1.7
Dividend Yield0.65%
Beta (Volatility)1.18
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $15.10 (14%)
Low: $12.94High: $28.00
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$43.20-71.2% upside

Insider Buys

6

$52.37M

Insider Sales

2

$4.50M

Total Volume

$56.87M

8 transactions

Net Activity

+$47.87M

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
100CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

No Recent Signal

Key Drivers

  • •Strong buying bias: purchases represent 92% of total transaction value.
  • •Cluster buying: 6 unique insiders purchased shares, showing strong alignment.
  • •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
W
1

Walsh Colin

Dir

1 buys1 sells

$12.54M total

G
2

Goldman Sachs Group Inc

Former 10% Owner

1 buys1 sells

$12.54M total

R
3

Redmile Group, LLC

10%

1 buys0 sells

$10.20M total

F
4

Frazier Life Sciences Xi, L.P.

10%

1 buys0 sells

$10.00M total

V
5

Venbio Global Strategic Fund Iv, L.P.

10%

1 buys0 sells

$6.50M total

Trading History
ATTO insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Aug 5, 2026

3 months ago

Walsh Colin

Dir

Director
Buy585.0K$17.58$10.29M

Aug 5, 2026

3 months ago

Walsh Colin

Dir

Director
Sell105.8K$21.28$2.25M

Aug 5, 2026

3 months ago

Goldman Sachs Group Inc

Former 10% Owner

10% Owner
Buy585.0K$17.58$10.29M

Aug 5, 2026

3 months ago

Goldman Sachs Group Inc

Former 10% Owner

10% Owner
Sell105.8K$21.28$2.25M

Aug 6, 2026

3 months ago

Venbio Global Strategic Fund Iv, L.P.

10%

10% Owner
Buy382.4K$17.00$6.50M

Aug 6, 2026

3 months ago

Redmile Group, LLC

10%

10% Owner
Buy600.0K$17.00$10.20M

Aug 6, 2026

3 months ago

Sanofi

10%

10% Owner
Buy300.0K$17.00$5.10M

Aug 6, 2026

3 months ago

Frazier Life Sciences Xi, L.P.

10%

10% Owner
Buy588.2K$17.00$10.00M
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
ATTO Buy Conviction92%
Industry Rank#0 of 569
Volume Contribution0.3%
Total Industry Activity$16.52B

ATTO has an insider buy conviction of 92%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for ATTO

Over the last 90 days, corporate insiders at ATTO (ATTO) engaged in a total of 8 transactions reported via SEC Form 4 filings. Among these, 6 were open-market purchases and 2 were sales. The total volume of insider trading reached $56.87M.

The net insider activity for ATTO shows a net buying bias of $47.87M. This activity represents a 92% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Purchase by Walsh Colin (Dir), who traded 585.0K shares valued at $10.29M on Aug 5, 2026.

Live Market News & Developments
Aggregated real-time headlines for ATTO (ATTO)
6 updates

Attovia Therapeutics Inc. Stock Grades | ATTO

Barron'sYesterday

Over 4 million shares underpin venBio’s reported passive stake in Attovia Therapeutics (ATTO).

Stock Titan3d ago

symbol__ Stock Quote Price and Forecast

CNN112d ago

Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits

Yahoo Finance60d ago

Attovia Therapeutics (NasdaqGM:ATTO) Stock Forecast & Analyst Predictions

Simply Wall St10d ago

Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO

Fierce Biotech107d ago

FAQs About ATTO Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for ATTO.

Based on SEC Form 4 disclosures, the Insider Confidence Score for ATTO is currently 100/100, which reflects a strong accumulation bias. This calculation accounts for a total of 6 purchases and 2 sales by company executives over the last 90 days.

The CEO Conviction Index for ATTO is rated as "No Recent Signal". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.